Clinical outcomes of direct oral anticoagulants in patients with thrombosis in unusual sites: Insights from a tertiary care center
Sergio Moragón-Ledesma a), b), c); Rubén Alonso-Beato a), b), c); Francisco Galeano-Valle a), b), c); Lucía Ordieres-Ortega a), b), c); Marina López-Rubio a), b), c); Marta-Olimpia Lago-Rodríguez a), b), c); Luis Antonio Alvarez-Sala-Walther a), b), c); Pablo Demelo-Rodríguez a b c d
a) Venous Thromboembolism Unit, Internal Medicine Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
b) School of Medicine, Universidad Complutense de Madrid, Spain
c) Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
d) School of Medicine, Universidad CEU San Pablo, Madrid, Spain
Highlights
• DOACs are the gold standard for venous thromboembolism (VTE) treatment, but their use is controversial in several clinical situations.
• The management of thrombosis in unusual sites (TUS) is either based on expert consensus or extrapolated from lower limb DVT.
• Anticoagulation is recommended for patients with TUS, but the use of DOACs in patients with TUS remains limited.
• Real-world data suggest that DOACs could be a useful for managing TUS, showing similar outcomes to Vitamin-K antagonists (VKAs).
• This study provides pragmatic data on TUS treatment with DOACs, which remain underrepresented in randomized trials for TUS.